ConductScience.org, home

Paper40940933

Immunotherapy-Associated Cardiotoxicity: Current Insights and Future Directions for Precision Cardio-Oncology.

Stefanou E and 3 others. Cancers (Basel), 2025. Cited by 6 papers, by iCite.

Cite this record

ConductScience Library. Immunotherapy-Associated Cardiotoxicity: Current Insights and Future Directions for Precision Cardio-Oncology. Papers, record 40940933. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40940933

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Immunotherapy-Associated Cardiotoxicity: Current Insights and Future Directions for Precision Cardio-Oncology.
PubMed
Journal
Cancers (Basel)
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
6
iCite
Relative citation ratio, by iCite
1.59, provisional
iCite
Revised in PubMed
2025-09-16
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Stefanou EEleni
2Tsitsinakis GGeorgios
3Karageorgou DDimitra
4Kole CChristohttps://orcid.org/0000-0003-4695-3723

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References209

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
111209085Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.Science2001https://conductscience.org/library/papers/11209085PubMed
234986285Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.N Engl J Med2022https://conductscience.org/library/papers/34986285PubMed
330074493Cardiovascular oncology: exploring the effects of targeted cancer therapies on atherosclerosis.Curr Opin Lipidol2018https://conductscience.org/library/papers/30074493PubMed
429434334Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'.Nat Rev Clin Oncol2018https://conductscience.org/library/papers/29434334PubMed
529385370Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.N Engl J Med2018https://conductscience.org/library/papers/29385370PubMed
628403786Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.Curr Med Chem2018https://conductscience.org/library/papers/28403786PubMed
727554835Nivolumab-Induced Pericardial Tamponade: A Case Report and Discussion.Cardiology2017https://conductscience.org/library/papers/27554835PubMed
829536852Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis.Lancet2018https://conductscience.org/library/papers/29536852PubMed
929567210Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.J Am Coll Cardiol2018https://conductscience.org/library/papers/29567210PubMed
1032848787Pharmacogenomics as a Tool to Limit Acute and Long-Term Adverse Effects of Chemotherapeutics: An Update in Pediatric Oncology.Front Pharmacol2020https://conductscience.org/library/papers/32848787PubMed
1124876563Current concepts in the diagnosis and management of cytokine release syndrome.Blood2014https://conductscience.org/library/papers/24876563PubMed
1234227272Cardiac Toxicities Associated with Immune Checkpoints Inhibitors: Mechanisms, Manifestations and Management.Korean Circ J2021https://conductscience.org/library/papers/34227272PubMed
1332893704Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio-Oncology Guidelines.J Am Heart Assoc2020https://conductscience.org/library/papers/32893704PubMed
1427632680Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.Crit Care Med2017https://conductscience.org/library/papers/27632680PubMed
1536636447Cardiotoxicity of T-Cell Antineoplastic Therapies: JACC: CardioOncology Primer.JACC CardioOncol2022https://conductscience.org/library/papers/36636447PubMed
1638544797Evaluation of all-cause mortality and cardiovascular safety in patients receiving chimeric antigen receptor T cell therapy: a prospective cohort study.EClinicalMedicine2024https://conductscience.org/library/papers/38544797PubMed
1731988143Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors.J Immunother Cancer2020https://conductscience.org/library/papers/31988143PubMed
1829461982Immune-mediated Pericarditis With Pericardial Tamponade During Nivolumab Therapy.J Immunother2018https://conductscience.org/library/papers/29461982PubMed
1932231332Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia.Nat Rev Cardiol2020https://conductscience.org/library/papers/32231332PubMed
2035669482Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Solid Tumors: Real-World Incidence, Risk Factors, and Prognostic Analysis.Front Cardiovasc Med2022https://conductscience.org/library/papers/35669482PubMed

See all 209 referencesDownload CSV of references

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.

PMIDTitleJournalYearIn PapersSource
42807136Immune checkpoint inhibitor-associated arrhythmias: clinical challenges, artificial intelligence-enhanced monitoring, and management strategies.Front Cardiovasc Med2026https://conductscience.org/library/papers/42807136PubMed
42587686Cardiovascular Complications Associated with Uro-Oncology Treatments-A Primer for the Clinician.Diagnostics (Basel)2026https://conductscience.org/library/papers/42587686PubMed
42488081Immune Checkpoint Inhibitor Associated Myopathy with Concurrent Myocardial Injury: A Retrospective Cohort Study.Int J Gen Med2026https://conductscience.org/library/papers/42488081PubMed
42318367Nivolumab-Associated Cardiac Manifestation of Cutaneous T-Cell Lymphoma in a Patient With Concurrent Renal Cell Carcinoma.Mayo Clin Proc Innov Qual Outcomes2026https://conductscience.org/library/papers/42318367PubMed
42228348Clinical spectrum and mechanistic insights into cardiotoxicity from cancer therapies.J Thromb Thrombolysis2026https://conductscience.org/library/papers/42228348PubMed
41669678Guarding the heart in the era of immunotherapies: insights for cardio-oncology practice.Front Pharmacol2026https://conductscience.org/library/papers/41669678PubMed
41592248Evidence of Cardiotoxic Immune Activation by Triple Immune Checkpoint Blockade: A Translational Alert for Clinical Surveillance in Patients With Cancer.J Cardiovasc Pharmacol2026https://conductscience.org/library/papers/41592248PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40940933

GET https://conductscience.org/api/papers/v1/40940933/references?page=2